Lixisenatide for type 2 diabetes mellitus

Expert Opinion on Investigational Drugs

Volumn 20, Issue 4, 2011, Pages 549-557

  Christensen, Mikkel ^a   Knop, Filip K ^a   Vilsbøll, Tina ^a   Holst, Jens J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

AVE0010; GETGOAL; GLP 1; incretin mimetics; lixisenatide; type 2 diabetes

Indexed keywords

DRUG ANTIBODY; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PARACETAMOL; PLACEBO; SULFONYLUREA;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADD ON THERAPY; ANTIBODY PRODUCTION; APOPTOSIS; CELL PROTECTION; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TACHYPHYLAXIS; THYROID TUMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PEPTIDES;

EID: 79952690188     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.562191     Document Type: Review

References (49)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;20(1):4-14
2. Goke B. Islet cell function: alpha and beta cells-partners towards normoglycaemia. Int J Clin Pract 2008;62(Suppl s159):2-7 (Pubitemid 351229610)
3. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 2010;59(5):1117-25
4. Schernthaner G, Barnett AH, Betteridge DJ, et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010;53(7):1258-69
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203
6. Riddle MC. Therapy: what evidence should guide the use of thiazolidinediones? Nat Rev Endocrinol 2010;6(11):600-2
7. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5(5):262-9
8. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87(4):1409-39 (Pubitemid 350041474)
9. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87(3):1239-46 (Pubitemid 36121094)
10. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44(9):1126-31
11. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80(3):952-7
12. Christensen M, Knop FK. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr Diab Rep 2010;10(2):124-32
13. European Medicines Agency. European Public Assessment Reports - Byetta - Scientific Discussion [Internet]. Available from: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/ medicines/000698/human-med-000682. jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d125 [Cited 5 November 2010]
14. European Medicines Agency. European Public Assessment Reports - Victoza [Internet]. Available from: http://www. ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/001026/ human-med-001137.jsp&murl=menus/ medicines/medicines. jsp&mid=WC0b01ac058001d125 [Cited 9 November 2010]
15. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009;23(4):463-77
16. Thorkildsen C, Neve S, Larsen BD, et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003;307(2):490-6 (Pubitemid 37310661)
17. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010;164(2-3):58-64
18. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46(1):3-19 (Pubitemid 36237741)
19. Tews D, Werner U, Eckel J. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res 2008;40(3):172-80 (Pubitemid 351690520)
20. Werner U, Vandewalle B, Kerr Conte J, et al. U. The GLP-1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicity-induced insulin depletion and preserves beta-cell function in human pancreatic islets [abstract 11-OR]. Diabetes 2008;57(Suppl 1):A3-4
21. Haschke G, Haag-Diergarten S, Werner U, et al. The GLP-1 receptor agonist AVE0010 preserves beta cell function and insulin secretion after a 6 week treatment in male obese Zucker diabetic fatty rats - an isolated perfused pancreas study. Diabetologia 2006;49(Suppl 1):400-1
22. Moore MC, Werner U, Smith MS, et al. Effect of the glucagon like peptide-1 receptor agonist AVE0010 on postprandial hepatic glucose metabolism in the conscious dog. Diabetologia 2007;50(Suppl 1):S242
23. Werner U, Gerlach M, Hofmann M, Herling AW. The GLP-1 receptor agonist AVE0010 abolishes OGTT-induced blood glucose excursion in healthy, normoglycemic dog without risk of hypoglycaemia [abstract]. Diabetes 2007;56(Suppl 1):A129-30
24. Distiller L, Ruus PE. Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in type 2 diabetes patients [abstract 520-P]. 68th Ann Meet Am Diabetes Assoc; 08 June 2008
25. Liu Y, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patient with renal impairment [abstract 557-P]. 69 Ann Meet Am Diabetes Assoc
26. Becker RHA, Ruus P, Liu Y-H, Kapitza C. Restoration of insulin release with lixisenatide in patients with type 2 diabetes [poster 850]. EASD 46th Annual Meeting; 20-24 September; Stockholm, Sweden
27. Liu Y, Ruus P. Effect of the GLP-1 agonist AVE0010 on absorption of concomitant oral drugs [abstract 495-P]. 69 Ann Meet Am Diabetes Assoc; 2009
28. Rosenstock J, Ratner R. Post-meal effects of AVE0010, a once-daily GLP-1 receptor agonist, in type 2 diabetes inadequately controlled on metformin [abstract 564-P]. 69 Ann Meet Am Diabetes Assoc
29. Gerich JE, Fonseca VA. Monotherapy with GLP-1 receptor agonist, Lixisenatide, significantly improves glycaemic control in type 2 diabetic patients. Poster 830 at EASD 46th Annual Meeting; 20 - 24 September 2010; Stockholm, Sweden
30. Ratner R, Rosenstock J, Boka G. A dose-finding study of the new GLP-1 agonist AVE0010 in type 2 diabetes insufficiently controlled with metformin [abstract 433-P]. 68th Ann Meet Am Diabetes Assoc; 8 June 2008
31. Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010;27(9):1024-32
32. Feinglos M, Dailey G, Cefalu W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 2005;68(2):167-75 (Pubitemid 40602625)
33. Ward WK, Beard JC, Porte D. Clinical aspects of islet B-cell function in non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1986;2(3-4):297-313 (Pubitemid 16009511)
34. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007;28(3):253-83 (Pubitemid 46984828)
35. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53
36. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52(1):102-10 (Pubitemid 36042113)
37. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372(9645):1240-50
38. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374(9683):39-47
39. Vilsboll T, Toft-Nielsen MB, Krarup T, et al. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 2000;23(6):807-12 (Pubitemid 30414198)
40. Goke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268(26):19650-5
41. van Eyll B, Lankat-Buttgereit B, Bode HP, et al. Signal transduction of the GLP-1-receptor cloned from a human insulinoma. FEBS Lett 1994;348(1):7-13
42. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374(9701):1606-16
43. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33(6):1173-5
44. Kielgast U, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with residual beta cell function with the once-daily glucagon-like peptide-1 analogue liraglutide. 46th EASD Annual Meeting; 21 September 2010; Stockholm, Sweden
45. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109(8):962-5 (Pubitemid 38282847)
46. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287(6):E1209-15
47. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010;9:6
48. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662):473-81
49. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30(8):1448-60